IDEXX Laboratories (IDXX) has achieved a significant share price increase of 64.7% over the past year, outperforming the medical products industry’s growth of 2.8% and the S&P 500 Composite’s 17.7% gain. This upward trend is attributed to a strong performance in its Companion Animal Group (CAG) Diagnostics, which reported over 10% organic recurring revenue growth in Q3 2025.
Headquartered in Westbrook, ME, IDEXX generates revenues from the veterinary diagnostics market and expects 2025 revenues to reach $4.28 billion, up by 9.9% from the previous year. The Zacks Consensus Estimate forecasts 2025 earnings per share (EPS) to rise 21.2% year-over-year to $12.93. The company’s innovative software solutions, like the Vello pet owner engagement application, have shown significant adoption, further enhancing its market position.
